IL-6 blockade
Interleukin-6 (IL-6) plays an important role in the pathogenesis of rheumatoid arthritis (RA). Tocilizumab, anti-human IL-6 receptor monoclonal antibody developed in Japan, prevents IL-6 from binding to IL-6 receptor blocking IL-6 signal. The clinical and radiographic efficacy of tocilizumab has proved in many clinical studies. Tocilizumab monotherapy is superior to methotrexate, which has not proved in TNF inhibitors, although tocilizuab in combination with methotrexate is more effective than tocilizumab monotherapy in inducing remission. Hepatotoxicity and infection are adverse events to be careful about.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Nihon rinsho. Japanese journal of clinical medicine - 74(2016), 6 vom: 10. Juni, Seite 963-7 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Kaneko, Yuko [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 21.07.2016 Date Revised 19.12.2018 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM261465228 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM261465228 | ||
| 003 | DE-627 | ||
| 005 | 20231224195618.0 | ||
| 007 | tu | ||
| 008 | 231224s2016 xx ||||| 00| ||jpn c | ||
| 028 | 5 | 2 | |a pubmed24n0871.xml |
| 035 | |a (DE-627)NLM261465228 | ||
| 035 | |a (NLM)27311186 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Kaneko, Yuko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IL-6 blockade |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 21.07.2016 | ||
| 500 | |a Date Revised 19.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Interleukin-6 (IL-6) plays an important role in the pathogenesis of rheumatoid arthritis (RA). Tocilizumab, anti-human IL-6 receptor monoclonal antibody developed in Japan, prevents IL-6 from binding to IL-6 receptor blocking IL-6 signal. The clinical and radiographic efficacy of tocilizumab has proved in many clinical studies. Tocilizumab monotherapy is superior to methotrexate, which has not proved in TNF inhibitors, although tocilizuab in combination with methotrexate is more effective than tocilizumab monotherapy in inducing remission. Hepatotoxicity and infection are adverse events to be careful about | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Receptors, Interleukin-6 |2 NLM | |
| 650 | 7 | |a clazakizumab |2 NLM | |
| 650 | 7 | |a 4S38Z8RA9O |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 650 | 7 | |a sarilumab |2 NLM | |
| 650 | 7 | |a NU90V55F8I |2 NLM | |
| 650 | 7 | |a olokizumab |2 NLM | |
| 650 | 7 | |a PAI71R1D2W |2 NLM | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 700 | 1 | |a Takeuchi, Tsutomu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nihon rinsho. Japanese journal of clinical medicine |d 1961 |g 74(2016), 6 vom: 10. Juni, Seite 963-7 |w (DE-627)NLM000006971 |x 0047-1852 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2016 |g number:6 |g day:10 |g month:06 |g pages:963-7 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2016 |e 6 |b 10 |c 06 |h 963-7 | ||